September 2017

By Michael FitzhughStaff Writer Positive new pivotal data has shown that ZX-008, Zogenix Inc.’s re-imagining of a key component of the ill-fated obesity drug Fen-Phen, can significantly reduce seizure frequency in children with the rare genetic epilepsy, Dravet syndrome. The result kept Zogenix on track to seek U.S. and European approvals for the drug in […]

by

The largest-ever survey conducted on cannabidiol (CBD) users found 80 percent of respondents reporting the cannabinoid “very effective” or “extremely effective” in treating their respective conditions, with 42 percent reporting they actually stopped using traditional prescription and over-the-counter medicines and replacing them with CBD-based products. The study was conducted by HelloMD, one of the nation’s […]

by

Dive Brief: Zynerba Pharmaceuticals’ shares shot up by 52.5% after news on Thursday that its lead drug, ZYN002 cannabidiol gel met its primary endpoint in its FAB-C Phase 2 trial in children and adolescents with Fragile X syndrome. In the open label study of the orphan drug, patients had a 46% improvement from baseline on […]

by

+1  Certified massage therapist Jacquelyne Youngquist works her healing magic on client Deb Elson. For most of her adult life, Jacquelyne Youngquist of Copperopolis has dreamed of helping people heal themselves. Her dream became a reality on Sept. 11 when she opened Body and Mind massage studio in Copperopolis Town Square in Copperopolis. “I have […]

by

Shutterstock photo (RTTNews.com) – The following are some of the biotech stocks that made their way onto the Day’s Gainers Losers’ list of September 28, 2017. GAINERS 1. Zynerba Pharmaceuticals Inc. (ZYNE) Gained 52.50% to close Thursday’s (Sep.28) trading at $9.44. News: The Company reported positive top line results from its phase II trial of […]

by

ZYN002 successfully met the primary endpoint and showed clinically meaningful improvements Zynerba to host conference call and webcast today, September 28 at 8:30 am ET DEVON, Pa., Sept. 28, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments, today announced positive […]

by

ZYN002 successfully met the primary endpoint and showed clinically meaningful improvements Zynerba to host conference call and webcast today, September 28 at 8:30 am ET DEVON, Pa., Sept. 28, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments, today announced positive […]

by